CA3003149C - Eflornithine and sulindac, fixed dose combination formulation - Google Patents

Eflornithine and sulindac, fixed dose combination formulation Download PDF

Info

Publication number
CA3003149C
CA3003149C CA3003149A CA3003149A CA3003149C CA 3003149 C CA3003149 C CA 3003149C CA 3003149 A CA3003149 A CA 3003149A CA 3003149 A CA3003149 A CA 3003149A CA 3003149 C CA3003149 C CA 3003149C
Authority
CA
Canada
Prior art keywords
cancer
composition
tablet
sulindac
weight percent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3003149A
Other languages
English (en)
French (fr)
Other versions
CA3003149A1 (en
Inventor
Patrick Shannon
Roberto Carlos Bravo Gonzalez
Jean Ducassou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Prevention Pharmaceuticals Inc
Original Assignee
Cancer Prevention Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Prevention Pharmaceuticals Inc filed Critical Cancer Prevention Pharmaceuticals Inc
Priority claimed from PCT/US2016/059689 external-priority patent/WO2017075576A1/en
Publication of CA3003149A1 publication Critical patent/CA3003149A1/en
Application granted granted Critical
Publication of CA3003149C publication Critical patent/CA3003149C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3003149A 2015-10-30 2016-10-31 Eflornithine and sulindac, fixed dose combination formulation Active CA3003149C (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201562248810P 2015-10-30 2015-10-30
US62/248,810 2015-10-30
US201662358698P 2016-07-06 2016-07-06
US62/358,698 2016-07-06
EP16306430.6 2016-10-28
EP16306429 2016-10-28
EP16306429.8 2016-10-28
EP16306430 2016-10-28
PCT/US2016/059689 WO2017075576A1 (en) 2015-10-30 2016-10-31 Eflornithine and sulindac, fixed dose combination formulation

Publications (2)

Publication Number Publication Date
CA3003149A1 CA3003149A1 (en) 2017-05-04
CA3003149C true CA3003149C (en) 2023-10-31

Family

ID=57256487

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3003149A Active CA3003149C (en) 2015-10-30 2016-10-31 Eflornithine and sulindac, fixed dose combination formulation

Country Status (14)

Country Link
US (4) US10973790B2 (es)
EP (1) EP3368029A1 (es)
JP (3) JP2018536707A (es)
KR (2) KR20180069068A (es)
CN (1) CN108366982A (es)
AU (1) AU2016343851B2 (es)
BR (1) BR112018008651A2 (es)
CA (1) CA3003149C (es)
CL (1) CL2018001157A1 (es)
CO (1) CO2018005491A2 (es)
HK (1) HK1258284A1 (es)
IL (1) IL259009A (es)
MA (1) MA43114A (es)
MX (1) MX390899B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10973790B2 (en) 2015-10-30 2021-04-13 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
KR102592801B1 (ko) * 2016-10-06 2023-10-20 오버스 쎄라퓨틱스, 인코포레이티드 에플로르니틴의 투여를 위한 제형
WO2020236562A1 (en) * 2019-05-17 2020-11-26 Cancer Prevention Pharmaceuticals, Inc. Methods for treating familial adenomatous polyposis
CN119909027B (zh) * 2025-01-21 2025-11-18 福安药业集团宁波天衡制药有限公司 一种稳定的舒林酸片及其制备方法

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4309442A (en) 1977-07-11 1982-01-05 Merrell Toraude Et Compagnie Method for controlling fertility in mammals
US4413141A (en) 1977-07-11 1983-11-01 Merrell Toraude Et Compagnie 2-(Difluoromethyl)-2,5-diaminopentanoic acid
US4330559A (en) 1977-07-11 1982-05-18 Merrell-Toraude Et Cie Method of treating benign prostatic hypertrophy
US4499072A (en) 1982-11-29 1985-02-12 Merrell Dow Pharmaceuticals Inc. Process for treating diseases with ODC inhibitors
US4859452A (en) 1986-01-17 1989-08-22 Board Of Regents, The University Of Texas System Methods for the reduction of difluoromethylornithine associated toxicity
US4925835A (en) 1986-05-01 1990-05-15 Sloan-Kettering Institute For Cancer Research Aziridinyl putrescine containing compositions and their uses in treating prostate cancer
US5002879A (en) 1986-05-06 1991-03-26 Merrell Dow Pharmaceuticals Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor
FR2706255B1 (fr) 1993-06-17 1995-10-27 Univ Rennes Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques.
US5843929A (en) 1996-03-22 1998-12-01 Mayo Foundation For Medical Education And Research Chemoprevention of metachronous adenomatous colorectal polyps
AU5200098A (en) * 1996-11-01 1998-05-29 Ilex Oncology, Inc. Sustained release formulation containing dfmo
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
JP2002509884A (ja) 1998-03-28 2002-04-02 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ザ・ユニバーシティ・オブ・アリゾナ 癌の化学防御におけるｄｆｍｏ及びスリンダクの組合せ
US7700568B2 (en) 1998-06-30 2010-04-20 Sloan-Kettering Institute For Cancer Research Uses of DNA-PK
US20050037090A1 (en) 1998-12-23 2005-02-17 Mckearn John P. Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent
PL349216A1 (en) 1998-12-23 2002-07-01 Searle & Co Method of using a cyclooxygenase-2 inhibitor and a matrix metalloproteinase inhibitor as a combination therapy in the treatment of neoplasia
US6753422B2 (en) 1999-03-01 2004-06-22 O'brien Thomas G. Odc allelic analysis method for assessing carcinogenic susceptibility
EP1178795A1 (en) 1999-05-17 2002-02-13 Ilex Oncology, Inc. Dfmo and celecoxib in combination for cancer chemoprevention and therapy
WO2001068076A2 (en) 2000-03-07 2001-09-20 Ilex Oncology, Inc. D-enantiomer of dfmo and methods of use thereof for treating cancer
US6602910B2 (en) 2000-03-07 2003-08-05 Ilex Oncology, Inc. D-enantiomer of DFMO and methods of use therefor
JP2004506683A (ja) 2000-08-24 2004-03-04 ザ　リージェンツ　オブ　ザ　ユニバーシティ　オブ　カリフォルニア α−ジフルオロメチルオルニチン（ＤＦＭＯ）は、ヒト前立腺におけるポリアミンレベルを抑制する
GB0125492D0 (en) * 2001-10-24 2001-12-12 Astrazeneca Ab Formulation
US7211602B2 (en) 2001-11-16 2007-05-01 Als Therapy Development Foundation, Inc. Treatment of neurodegenerative disorders through the modulation of the polyamine pathway
JP2006515861A (ja) * 2002-11-29 2006-06-08 フォレスト ラボラトリーズ インコーポレーテッド イブプロフェンとオキシコドンを含有する単位剤形での急性痛の治療方法
US20100009929A1 (en) 2004-03-29 2010-01-14 Cheng Jin Q Compositions including triciribine and bortezomib and derivatives thereof and methods of use thereof
US20070043096A1 (en) * 2005-07-18 2007-02-22 Horizon Therapeutics, Inc. Unit dose form with ibuprofen-famotidine admixture
US9072778B2 (en) 2005-12-20 2015-07-07 University Of Hawaii Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors
PL2043637T3 (pl) 2006-07-18 2012-06-29 Horizon Pharma Usa Inc Sposoby i leki do podawania ibuprofenu
EP2185138B1 (en) * 2007-07-19 2016-09-07 Takeda Pharmaceutical Company Limited Solid preparation comprising alogliptin and metformin hydrochloride
CN101784277A (zh) 2007-08-01 2010-07-21 希格马托制药工业公司 儿科肿瘤的治疗
WO2009022670A1 (ja) * 2007-08-10 2009-02-19 Takeda Pharmaceutical Company Limited 速崩壊性錠剤
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
WO2009052518A2 (en) * 2007-10-19 2009-04-23 Aspen Benefits Group, Llc Methods and compositions directed to reduction of facial hair hirsutism in females
US20110158983A1 (en) 2008-03-05 2011-06-30 Newell Bascomb Compositions and methods for mucositis and oncology therapies
WO2010056919A2 (en) * 2008-11-12 2010-05-20 Kyphia Pharmaceuticals, Inc. Eflornithine prodrugs, conjugates and salts, and methods of use thereof
CN102361622B (zh) 2008-12-08 2013-11-20 宝洁公司 具有疏水性表面驻留涂层的制品形式的个人护理组合物
ES2507145T3 (es) 2009-05-14 2014-10-14 Arizona Board Of Regents On Behalf Of University Of Arizona Diagnóstico y tratamientos del carcinoma, basado en el genotipo de ODC1
SG176096A1 (en) 2009-05-20 2011-12-29 Ranbaxy Lab Ltd Liquid dosage forms of isotretinoin
CN101898978A (zh) 2009-05-31 2010-12-01 徐锋 依氟鸟氨酸前药和偶合物及其使用方法
US20110256161A1 (en) 2010-04-19 2011-10-20 Aminex Therapeutics Inc. Methods for enhancing immune response
US9598734B2 (en) 2010-04-29 2017-03-21 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy
CA2799431A1 (en) 2010-05-14 2011-11-17 Cancer Prevention Pharmaceuticals, Inc. Cancer prevention and treatment methods based on dietary polyamine content
WO2011159769A2 (en) * 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
WO2011160119A2 (en) 2010-06-19 2011-12-22 Memorial Sloan-Kettering Cancer Center Anti-gd2 antibodies
WO2014070767A1 (en) 2012-10-29 2014-05-08 Arizona Board Of Regents On Behalf Of University Of Arizona Predictive markers for polyamine inhibitor cancer therapies
GB2513299A (en) 2013-03-12 2014-10-29 Cellact Pharma Gmbh Biomedizinzentrum Compounds for targeting cancer stem cells
WO2015054133A1 (en) * 2013-10-07 2015-04-16 Bristol-Myers Squibb Company Hiv treatment formulation of atazanavir and cobicistat
KR20150079373A (ko) * 2013-12-30 2015-07-08 한미약품 주식회사 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
US10655183B2 (en) 2014-06-18 2020-05-19 Arizona Board Of Regents On Behalf Of University Of Arizona Carcinoma diagnosis and treatment based on ODC1 genotype
JP2018507910A (ja) 2015-02-12 2018-03-22 ジ・アリゾナ・ボード・オブ・リージェンツ・オン・ビハーフ・オブ・ジ・ユニバーシティ・オブ・アリゾナ 神経芽細胞腫を治療する方法
US10973790B2 (en) 2015-10-30 2021-04-13 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
WO2017075576A1 (en) 2015-10-30 2017-05-04 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation

Also Published As

Publication number Publication date
JP2022028814A (ja) 2022-02-16
US20200009098A1 (en) 2020-01-09
US20210267926A1 (en) 2021-09-02
JP2024102339A (ja) 2024-07-30
BR112018008651A2 (pt) 2018-10-30
AU2016343851A1 (en) 2018-05-10
JP2018536707A (ja) 2018-12-13
KR20180069068A (ko) 2018-06-22
MX2018005350A (es) 2018-08-14
IL259009A (en) 2018-07-31
MX390899B (es) 2025-03-21
AU2016343851B2 (en) 2022-04-07
US10973790B2 (en) 2021-04-13
CL2018001157A1 (es) 2018-09-07
US12350246B2 (en) 2025-07-08
US20240173284A1 (en) 2024-05-30
US11529326B2 (en) 2022-12-20
JP7592001B2 (ja) 2024-11-29
HK1258284A1 (zh) 2019-11-08
CN108366982A (zh) 2018-08-03
CO2018005491A2 (es) 2018-06-12
US11925613B2 (en) 2024-03-12
CA3003149A1 (en) 2017-05-04
MA43114A (fr) 2018-09-05
US20230172887A1 (en) 2023-06-08
EP3368029A1 (en) 2018-09-05
KR20240162560A (ko) 2024-11-15

Similar Documents

Publication Publication Date Title
US12350246B2 (en) Eflornithine and sulindac, fixed dose combination formulation
TWI702953B (zh) 包含ａｚｄ９２９１之醫藥組合物及錠劑以及其用途
KR101699912B1 (ko) 1종 이상의 푸마르산 에스테르를 침식 매트릭스에 함유하는 제제
BR112012028035B1 (pt) formulação de liberação imediata
US10207002B2 (en) Sustained release formulation and tablets prepared therefrom
JP7431886B2 (ja) 新規テビペネムピボキシルの即放性および調節放出性経口剤形
CN111278433A (zh) 尼拉帕尼制剂
WO2017075576A1 (en) Eflornithine and sulindac, fixed dose combination formulation
CA3104695A1 (en) Formulations of ag10
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
US8613949B2 (en) Galenical formulations of organic compounds
RU2669920C2 (ru) Фармацевтическая композиция с контролируемым высвобождением, основанная на прионовой кислоте
CN105311635A (zh) 可调控释放度的高载药量的医药组合物及其制备方法
TWI743059B (zh) 二氟甲基鳥氨酸及舒林酸（ｓｕｌｉｎｄａｃ），固定劑量組合調配物
JP6735007B2 (ja) エンタカポン含有医薬組成物
CA3235787A1 (en) Methods of treating patients having type 1 diabetes with eflornithine
EP3251669B1 (en) Solid composition of pyrrole carboxamide
US20130236538A1 (en) Pharmaceutical compositions of ibuprofen and famotidine
JP2012520895A (ja) バルサルタンおよびアリスキレンの一定用量の組合せのガレヌス製剤
JP2019530755A (ja) セレコキシブを含む錠剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20211008

EEER Examination request

Effective date: 20211008

EEER Examination request

Effective date: 20211008

EEER Examination request

Effective date: 20211008

EEER Examination request

Effective date: 20211008

EEER Examination request

Effective date: 20211008

EEER Examination request

Effective date: 20211008

EEER Examination request

Effective date: 20211008